If you have searched hyperbaric oxygen therapy, you have probably found two different internets. One describes a hospital treatment with a short, specific list of conditions behind it. The other describes a chamber for fatigue, brain fog, recovery and aging. Both sets of pages cite research. Neither usually tells you that the research behind hyperbaric oxygen is not one body of evidence — it is a different body of evidence for every condition, and the strength varies enormously from one to the next.
A 2026 multicentre study published in the Journal of Anesthesia, Analgesia and Critical Care is unusually useful here, because it did not test whether hyperbaric oxygen works. It simply recorded what ten hyperbaric centres actually used it for, and what happened afterward. Read next to a meta-analysis of one of the conditions people search for most, it explains most of the disagreement you have run into.
What a 2026 multicentre study found the treatment is actually used for
The ITA-OTI study enrolled 327 consecutive patients across ten hyperbaric centres, each centre recruiting for twelve consecutive weeks between April 2024 and October 2025. Nearly three quarters of treatments, 73.7%, were elective; 26.3% were urgent.
The indication list is the part worth sitting with. The single most frequent reason for treatment was sudden hearing loss, at 35.8%. Carbon monoxide poisoning accounted for 19.9%, mixed or anaerobic soft tissue infections for 12.2%, and chronic ulcers for 8.9%. Everything else was, in the authors’ words, less represented across the cohort. The conditions that dominate consumer search results were not what these centres were mostly treating.
The results did not come out as one number — they split by indication
Across the whole cohort, clinical assessment at 30 days after the last session recorded complete resolution in 47.1%, partial resolution in 34.3%, and no benefit in 13.5%, with 17 patients lost to follow-up. That single average is almost useless on its own, and the paper’s own breakdown shows why.
In carbon monoxide poisoning, 98.2% of patients were recorded as completely resolved. In sudden hearing loss — the most common indication in the study — 28.8% were complete, 45.9% partial, and 25.2% recorded no benefit at all. Soft tissue infections landed between them at 52.5% complete. Same treatment, same ten centres, same thirty-day window, and outcomes that range from near-universal resolution to one in four patients with nothing to show. The indication, not the chamber, is doing most of the work.
Why that one table explains most of what you have read online
A page citing the carbon monoxide figure is accurate. A page citing the hearing-loss figure is also accurate. A page quoting the 47.1% average is accurate too, and describes nobody in particular. It is the same pattern we wrote about when comparing what the laboratory evidence shows against what the clinical evidence shows for oxygen-based therapies. So the useful question to ask a clinic is not whether hyperbaric oxygen has research behind it, because it does. It is what the research behind your reason for considering it looks like, and whether anyone has measured it in a trial rather than a case series.
Where the conditions people actually search for sit in the evidence
Fibromyalgia is a fair test case, because it is one of the conditions most often raised in consultations and it has an actual meta-analysis behind it. A 2023 analysis in Clinics and Practice — older than the Italian study, and worth naming as older — pooled every randomized controlled trial it could find. That came to four trials and 163 participants in total, 82 treated and 81 controls.
The pooled results split in a way patients should know about. Fibromyalgia Impact Questionnaire scores improved, at a standardized mean difference of −1.57 (95% CI −2.34 to −0.80), and tender point counts improved, at −2.50 (−3.96 to −1.05). Pain itself did not reach statistical significance: −1.68, with a confidence interval from −4.47 to 1.11 and heterogeneity of 96%. The authors also report that none of the four trials was rated low risk of bias, and state plainly that level 1 evidence is lacking and that larger trials with unified regimens and longer follow-up are needed. Hyperbaric oxygen is not an FDA-approved treatment for fibromyalgia, chronic fatigue, or post-viral illness.
Nobody has standardized how many sessions a course should be
The Italian study’s own stated conclusion is that treatments looked broadly similar across its ten centres, with heterogeneity mainly regarding the number of sessions per patient. Patients received a median of 16 sessions, with an interquartile range of 6 to 24 — a fourfold spread inside a single national study of centres following the same guidelines.
The fibromyalgia trials show the same thing more starkly. Of the four pooled, two used 40 daily sessions, one used 60, and one used 15, all of them five days a week at 90 minutes. The review notes there is no consensus regarding therapy sessions and that it could not identify what was driving the heterogeneity it found, which ran from 0% to 96% depending on the outcome. A course of 15 and a course of 60 are not the same intervention being tested twice.
What the side-effect data actually reports
Two independent sources point the same way, and both point at the ears. In the Italian study, 23 of 327 patients had a session interrupted: 19 because of difficulty equalizing ear pressure, four for other non-life-threatening reasons. Of those 19, ten did not continue treatment. One patient needed medical care for ear barotrauma. Chest imaging was performed in 76.5% of cases and 99.4% showed no sign of barotrauma, and the authors report no serious adverse events.
The fibromyalgia meta-analysis found that hyperbaric oxygen significantly increased the incidence of side effects, at a risk ratio of 24.97 (95% CI 3.75 to 166.47), most of them middle ear barotrauma, which the authors describe as resolving spontaneously. Taken together: side effects are common enough to matter, overwhelmingly ear-related, usually mild, and in a meaningful minority of patients enough to end the course.
Even the field’s own name for it is not settled
A 2026 position statement from the Undersea and Hyperbaric Medical Society makes a point that sounds like housekeeping and is not. The Society notes that terminology in hyperbaric medicine has historically lacked standardization, with multiple terms and abbreviations used interchangeably across clinical practice, publications, educational materials and public communication. It endorses hyperbaric oxygen treatment as the preferred term and recommends the abbreviation HBO2 in place of HBOT.
The reason it matters to a patient is in the statement itself: the Society says inconsistent naming may contribute to confusion regarding the definition, regulation, clinical standards and physician oversight associated with the treatment, and that consistent naming is intended to improve clarity for clinicians, researchers, regulators, payers, referring providers and the public. When a specialty society says its own field’s naming confuses the question of oversight, a confused search result is not the reader’s fault.
Who is generally not a good candidate
This is decided in a consultation, not an article, but the published evidence points at a few groups plainly enough to say out loud.
- Anyone who cannot equalize middle ear pressure. Difficulty equalizing was the single most common reason a session was stopped in the Italian study, and it ended treatment for ten patients.
- Anyone seeking it for an emergency indication. Carbon monoxide poisoning, decompression illness and acute necrotizing infection are hospital-based, often urgent treatments — a quarter of the Italian cohort was treated urgently. Venturis does not provide emergency or inpatient hyperbaric care, and a patient who needs it should be in a hospital.
- Anyone being offered it instead of a diagnosis. A quarter of the Italian cohort, 25.7%, needed other therapies including surgery during their hyperbaric course. It is an adjunct in that literature, not a substitute for working out what is wrong.
Four questions worth asking before you book a course
- What indication are you treating me for, and what is the evidence behind that specific use? Any clinic should be able to name it and describe the study design, not just the mechanism.
- How many sessions, and what decides whether we stop? Ask what would count as no response, and when that gets reviewed.
- What outcome are we measuring, and when? The Italian study’s own limitation was that resolution was judged by non-standardized clinical assessment with no pre-specified criteria. Your course should do better than that.
- Who is overseeing it, and what happens if I cannot clear my ears? Both sources above make ear complications the most likely thing to go wrong.
Talk it through with someone who will name the indication
If you are weighing a hyperbaric course in the Oklahoma City metro, the conversation worth having first is what the evidence behind your specific reason looks like, and whether it is the right next step at all.
Venturis Clinic
7917 N May Ave, Suite B, Oklahoma City, OK 73120
Phone: (405) 848-7246
Serving Oklahoma City, Edmond, Moore, Norman, Yukon, Mustang, Piedmont, Bethany, Warr Acres and Nichols Hills.
Frequently asked questions
What is hyperbaric oxygen therapy used for?
In a 2026 study of ten hyperbaric centres, the most frequent indications were sudden hearing loss (35.8%), carbon monoxide poisoning (19.9%), mixed or anaerobic soft tissue infections (12.2%) and chronic ulcers (8.9%). Other uses were far less represented in that cohort.
Does hyperbaric oxygen therapy work?
That depends almost entirely on the condition. In the same study, 98.2% of carbon monoxide patients were recorded as completely resolved at 30 days, while among sudden hearing loss patients 28.8% were complete and 25.2% recorded no benefit. One average cannot describe both.
How many hyperbaric oxygen sessions do you need?
There is no standardized number. Patients in the 2026 multicentre study received a median of 16 sessions, with an interquartile range of 6 to 24. Pooled fibromyalgia trials used courses of 15, 40, 40 and 60 sessions. Ask what decides when yours is reviewed.
What are the side effects of hyperbaric oxygen therapy?
Mostly ear-related. In the 2026 study, 19 of 327 patients had a session interrupted for difficulty equalizing ear pressure and one needed care for ear barotrauma, with no serious adverse events reported. A fibromyalgia meta-analysis found side effects significantly more common with treatment, mainly middle ear barotrauma.
Is hyperbaric oxygen therapy approved for fibromyalgia or chronic fatigue?
No. Hyperbaric oxygen is not an FDA-approved treatment for fibromyalgia, chronic fatigue or post-viral illness. A 2023 meta-analysis of four trials and 163 participants found questionnaire and tender point scores improved while pain did not reach significance, and the authors state level 1 evidence is lacking.
Is hyperbaric oxygen therapy available in Oklahoma City?
Yes. Venturis Clinic offers hyperbaric oxygen therapy alongside other alternative and functional medicine services at 7917 N May Ave, Suite B. Candidates are typically evaluated during a consultation, and results vary from patient to patient.
Sources
- Ippolito M, Martani L, Noto A, et al. Indications, therapeutic modalities and clinical outcomes of hyperbaric oxygen therapy in Italy, the ITA-OTI Study: a multicentre prospective observational study. Journal of Anesthesia, Analgesia and Critical Care, 2026;6(1):96. DOI: 10.1186/s44158-026-00403-w
- Cao C, Li Q, Zhang X, Varrassi G, Wang H. Effectiveness of Hyperbaric Oxygen for Fibromyalgia: A Meta-Analysis of Randomized Controlled Trials. Clinics and Practice, 2023;13(3):583–595. DOI: 10.3390/clinpract13030053
- O’Neill OJ, Kelly M, Shapshak D. UHMS Position Statement: Standardization of Terminology in Undersea and Hyperbaric Medicine: Adoption of Hyperbaric Oxygen Treatment. Undersea and Hyperbaric Medicine, 2026;53(3):541–542. PMID: 42826433
This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Individual results vary and no outcome is guaranteed. Venturis Clinic offers regenerative, functional, and alternative medicine services; some therapies discussed are not FDA-approved for the uses described. Talk with a qualified healthcare provider about your specific situation before beginning any treatment.
Wondering if this applies to you?
Every patient is different. Request a free 15-minute discovery call and our team will listen to what you have been dealing with and help you decide on a next step.
Request a free 15-minute discovery callor call (405) 848-7246